Prevalence of recurrent calcium-oxalate (CaOx) urolithiasis (UL) is up to fivefold higher in Crohn’s disease than in the general population. Treatment options are scarce and the risk of recurrent UL or progressive renal CaOx deposition, (oxalosis) based early end-stage renal failure (ESRF), subsequent systemic oxalosis, and recurrence in the kidney graft is pronounced. We aimed to find proof that secondary hyperoxaluria is the main risk factor for the devastating course and correlates with intestinal oxalate absorption.
24-h urines were collected and analyzed for urinary oxalate (Uox) in 27 pediatric (6–18 years) and 19 adult patients (20–62 years). In the 21 patients (8 adults and 13 children) with hyperoxaluria a [13C2]oxalate absorption test was performed under standardized dietary conditions.
Mean Uox was significantly higher in patients with UL or oxalosis (0.92 ± 0.57) compared with those without (0.53 ± 0.13 mmol/1.73 m2/24 h, p<0.05, normal < 0.5). Hyperoxaluria then significantly correlated with intestinal oxalate absorption (p< 0.05).
As UL/oxalosis has major implications for the general health in patients with Crohn’s disease (ESRF and systemic oxalosis), new medication, e.g. to reduce intestinal oxalate absorption, is definitely needed.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
VanDervoort K, Wiesen J, Frank R, Vento S, Crosby V, Chandra M, Trachtman H (2007) Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol 177:2300–2305
Sas DJ, Hulsey TC, Shatat IF, Orak JK (2010) Increasing incidence of kidney stones in children evaluated in the emergency department. J Pediatr 157:132–137
Andersson H, Bosaeus I, Fasth S, Hellberg R, Hulten L (1987) Cholelithiasis and urolithiasis in Crohn's disease. Scand J Gastroenterol 22:253–256
Hoppe B, Leumann E, von Unruh G, Laube N, Hesse A (2003) Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front Biosci 8:e437–e443
Neuhaus TJ, Belzer T, Blau N, Hoppe B, Sidhu H, Leumann E (2000) Urinary oxalate excretion in urolithiasis and nephrocalcinosis. Arch Dis Child 82:322–326
Holmes RP, Goodman HO, Assimos DG (2001) Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 59:270–276
Williams HE, Wandzilak TR (1989) Oxalate synthesis, transport and the hyperoxaluric syndromes. J Urol 141:742–749
Leumann E, Hoppe B (2001) The primary hyperoxalurias. J Am Soc Nephrol 12:1986–1993
Binder HJ (1974) Intestinal oxalate absorption. Gastroenterology 67:441–446
Dobbins JW, Binder HJ (1976) Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology 70:1096–1100
Chadwick VS, Modha K, Dowling RH (1973) Mechanism for hyperoxaluria in patients with ileal dysfunction. N Engl J Med 289:172–176
Booth CC, Babouris N, Hanna S, Macintyre I (1963) Incidence of hypomagnesaemia in intestinal malabsorption. Br Med J 2:141–144
Trinchieri A, Lizzano R, Castelnuovo C, Zanetti G, Pisani E (2002) Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease. Arch Ital Urol Androl 74:61–64
Rudman D, Dedonis JL, Fountain MT, Chandler JB, Gerron GG, Fleming GA, Kutner MH (1980) Hypocitraturia in patients with gastrointestinal malabsorption. N Engl J Med 303:657–661
Dobbins JW (1985) Nephrolithiasis and intestinal disease. J Clin Gastroenterol 7:21–24
Caudarella R, Rizzoli E, Pironi L, Malavolta N, Martelli G, Poggioli G, Gozzetti G, Miglioli M (1993) Renal stone formation in patients with inflammatory bowel disease. Scanning Microsc 7:371–379, discussion 379-380
Hylander E, Jarnum S, Frandsen I (1979) Urolithiasis and hyperoxaluria in chronic inflammatory bowel disease. Scand J Gastroenterol 14:475–479
Kyle J (1980) Urinary complications of Crohn's disease. World J Surg 4:153–160
Beck B, Habbig S, Feldkötter M, Wolf M, Bangen U, Michalk D, Stapenhorst L, Burst V, Stippel D, Fries J, Hoppe B (2008) How to handle the dilemma of ESRF and systemic oxalosis in short bowel syndrome from Crohn's disease - a potential application for Oxalobacter formigenes. Pediatr Nephrol 23:P065
Dick PT, Shuckett BM, Tang B, Daneman A, Kooh SW (1999) Observer reliability in grading nephrocalcinosis on ultrasound examinations in children. Pediatr Radiol 29:68–72
Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263
Sikora P, von Unruh GE, Beck B, Feldkotter M, Zajaczkowska M, Hesse A, Hoppe B (2008) [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int 73:1181–1186
von Unruh GE, Langer MA, Paar DW, Hesse A (1998) Mass spectrometric-selected ion monitoring assay for an oxalate absorption test applying [13C2]oxalate. J Chromatogr B: Biomed Sci Appl 716:343–349
Hoppe B, Jahnen A, Bach D, Hesse A (1997) Urinary calcium oxalate saturation in healthy infants and children. J Urol 158:557–559
Hylander E, Jarnum S, Jensen HJ, Thale M (1978) Enteric hyperoxaluria: dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease. Scand J Gastroenterol 13:577–588
Hesse A, Schneeberger W, Engfeld S, Von Unruh GE, Sauerbruch T (1999) Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2]oxalate. J Am Soc Nephrol 10 [Suppl 14]:S329–S333
Asplin JR (2002) Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am 31:927–949
Sikora P, Zajaczkowska M, Hoppe B (2009) Assessment of crystallization risk formulas in pediatric calcium stone-formers. Pediatr Nephrol 24:1997–2003
Laube N, Hoppe B, Hesse A (2005) Problems in the investigation of urine from patients suffering from primary hyperoxaluria type 1. Urol Res 33:394–397
von Unruh GE, Voss S, Sauerbruch T, Hesse A (2003) Reference range for gastrointestinal oxalate absorption measured with a standardized [13C2]oxalate absorption test. J Urol 169:687–690
el-Habet AE, el-Sewedy SM, el-Sharaky A, Gaafar NK, Abdel-Rafee A, Hamoud F (1987) Biochemical studies on bilharzial and nonbilharzial hyperoxaluria: effect of pyridoxine and allopurinol treatment. Biochem Med Metab Biol 38:1–8
Zimmermann DJ, Hesse A, von Unruh GE (2005) Influence of a high-oxalate diet on intestinal oxalate absorption. World J Urol 23:324–329
Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB (1999) Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 10 [Suppl 14]:S334–S340
Kumar R, Mukherjee M, Bhandari M, Kumar A, Sidhu H, Mittal RD (2002) Role of Oxalobacter formigenes in calcium oxalate stone disease: a study from North India. Eur Urol 41:318–322
Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS (2002) Oxalobacter formigenes and its potential role in human health. Appl Environ Microbiol 68:3841–3847
Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H (2006) Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 70:1305–1311
Electronic supplementary material
Below is the link to the electronic supplementary material.
(DOC 3944 kb)
About this article
Cite this article
Hueppelshaeuser, R., von Unruh, G.E., Habbig, S. et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn’s disease. Pediatr Nephrol 27, 1103–1109 (2012). https://doi.org/10.1007/s00467-012-2126-8
- Crohn’s disease
- Secondary hyperoxaluria
- Systemic oxalosis
- Renal failure